** Shares of Mayne Pharma Group MYX.AX soar 13.3% to A$5.30, their highest level since December 3, 2024

** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index .AORD

** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million) and A$32 million, up to four-fold jump from last year's A$8 million

** Revenue forecast between A$210 million and A$215 million, up to 14% growth

** Co expects to see continued growth in 2H25

** More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares

** MYX up 6.8% this year, including day's moves

($1 = 1.5995 Australian dollars)

(Reporting by Sameer Manekar in Bengaluru)

((Sameer.Manekar@thomsonreuters.com;))